ONXX
Onyx Pharmaceuticals

Conference date: August 8, 2013 @ 2:00 PM Pacific Time

Left up in case you want to analyse Onyx for its value within Amgen.

Amgen to Buy Onyx Pharmaceuticals (ONXX) for $125 per share [press release August 25, 2013]
Onyx Pharmaceuticals Sees 2013 Acceleration [January 7, 2013]
Kyprolis: Which Multiple Myeloma Patients Will Physicians Treat With It? [MyelomaBeacon, August 17, 2012]
Kyprolis Approved [July 20, 2012]
Onyx Pharmaceuticals New Back of Envelope [June 27, 2012]

Analyst Conference Call Summaries Available:

2013
Onyx Pharmaceuticals ONXX analyst conference summary Q4 2012
Onyx Pharmaceuticals ONXX analyst conference summary Q1 2013
Onyx Pharmaceuticals ONXX analyst conference summary Q2 2013
 
02/21/2013
05/07/2013
08/08/2013
 
Q4 2012
Q1 2013  
Q2 2013
 
2012
Onyx Pharmaceuticals ONXX analyst conference summary Q4 2011
Onyx Pharmaceuticals ONXX analyst conference summary Q1 2012
Onyx Pharmaceuticals ONXX analyst conference summary Q2 2012
Onyx Pharmaceuticals ONXX analyst conference summary Q3 2012
02/22/12
05/02/12
08/01/2012
11/01/2012 
Q4 2011
Q1 2012
Q2 2012
Q3 2012
2011
Onyx Pharmaceuticals ONXX analyst conference summary Q4 2010
Onyx Pharmaceuticals ONXX analyst conference summary Q1 2011
Onyx Pharmaceuticals ONXX analyst conference summary Q2 2011
Onyx Pharmaceuticals ONXX analyst conference summary Q3 2011
02/23/2011
 05/04/2011
08/03/2011 
11/02/2011
Q4 2010
Q1 2011  
Q2 2011  
Q3 2011
2010
Onyx Pharmaceuticals ONXX analyst conference summary Q4 2009
Onyx Pharmaceuticals ONXX analyst conference summary Q1 2010
Onyx Pharmaceuticals ONXX analyst conference summary Q2 2010
Onyx Pharmaceuticals ONXX analyst conference summary Q3 2010
02/23/2010
05/04/2010 
 08/04/2010
11/03/2010 
Q4 2009
 Q1 2010
 Q2 2010
Q3 2010  
2009
Onyx (ONXX) analyst conference summary Q4 2008
Onyx Pharmaceuticals ONXX analyst conference summary q1 2009
Onyx Pharmaceuticals ONXX analyst conference summary Q2 2009
Onyx Pharmaceuticals ONXX analyst conference summary Q3 2009
02/23/2009
05/06/2009
 08/04/2009
11/03/2009
Q4 2008
Q1 2009
 Q2 2009
Q3 2009  
2008
Onyx analyst conference summary Q3 2008
Onyx (ONXX) analyst conference summary Q2 2008
Onyx Q1 analyst conference summary 2008
Onyx Q4 2007 analyst conference summary
11/06/2008
08/05/2008
05/06/2008
02/19/2008
Q3 2008
Q2 2008
Q1 2008
Q4 2007
2007
Onyx analyst conference summary Q3 2007
ONXX Q2 2007 summary
ONXX summary
ONXX Q4 2006 summary
11/06/2007
08/07/2007
05/09/2007
02/15/2007
Q3 2007
Q2 2007
Q1 2007
Q4 2006
2006
ONXX Q3 2006 summary
ONXX Q2 2006 summary
ONXX Q1 2006 summary
11/07/2006
08/08/2006
05/05/2006
Q3 2006
Q2 2006
Q1 2006

Carfilzomib (Kyprolis) Recommended for Multiple Myeloma by FDA Committee [June 20, 2012 press release]
Onyx (ONXX) Sees New Product Upside [November 21, 2011]
Onyx Pharmaceuticals Gets $160 million for Nexavar, Plus Regorafenib Royalties [October 12, 2011]
Onyx Pharmaceuticals Readies Carfilzomib [August 17, 2011]
Onyx Pharmaceuticals ASH Conference [December 7, 2010]
Onyx Pharmaceuticals (ONXX) Jumps on Carfilzomib Revenue [November 22, 2010]
Onyx Pharmaceuticals Jumps on Carfilzomib Data [August 8, 2010]
Onyx Pharmaceuticals Acquires Proteolix, Carfilzomib [October 12, 2009]
Onyx Breast Cancer Trial Results [September 30, 2009]
Onyx Positive Surprise for Investors [November 11, 2008]
Onyx Chooses the Long Run [August 11, 2008]
Onyx In The Black [May 7, 2008]
Onyx (ONXX) Nexavar Trial and Q4 results comments [February 20, 2008]
Can Onyx Deliver? [May 10, 2007]

First bought on May 9, 2008

Onyx Web site:

Onyx Pharmaceuticals main page
Onyx Pharmaceuticals investor page

Onyx (ONXX) is a biotech or pharmaceutical company. Its primary product is Nexavar for kidney and liver cancer.

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. Before making or terminating an investment you should always verify any factual basis of your decision.